SHANGHAI, Dec. 1 /PRNewswire-Asia/ -- Shanghai ChemPartner, as the flagship subsidiary of ShangPharma, a leading China-based Contract Research Organization (CRO), today announced it is a winner of the 2009 Deloitte Technology Fast 50 China, ranking 3rd on the list of the fastest-growing high tech companies in China. The award is a testament to ChemPartner's outstanding three-year revenue growth from 2006 to 2008.
The results of the 2009 Deloitte Technology Fast 50 China Program were officially released at an award presentation ceremony in Beijing. ChemPartner was the only company from the pharmaceutical and healthcare sector in the Top 10 ranking.
"We are quite honored to be presented this award by Deloitte, which is a globally acknowledged independent professional agency and consulting partner," said Michael Hui, founder and CEO of Shanghai ChemPartner. "This is a remarkable recognition to our consistent efforts in strategically expanding and consolidating our R&D service portfolio, sharpening our core competence through improving internal operation efficiency."
"We will keep focusing more on our own development such as further optimizing operational efficiency and attracting and retaining talent. Developing business in this uncertain economic environment has taught us the importance of successful risk management; and we believe that improving productivity through careful strategic planning and innovation can help companies achieve sustainable growth." Michael Hui added.
Mr. William Chou, Deloitte China's National Leader of Technology, Media & Telecommunications, said, "Backed by the country's strong economic expansion and government support for technological innovation, there is still much room for the Chinese hi-tech industry to grow. Significant overseas and domestic investments in innovative and growing Chinese companies are also driving industry development. It has been exciting to witness this vibrant growth and development through the Deloitte Technology Fast 50 China Program over the past five years. The industry has continued to outperform, with many successful players contributing to its dynamic development."
Mr. Chou continued, "We are glad to see that Chinese hi-tech companies have invested a lot of effort into enhancing their competitiveness despite external challenges. Looking forward, most hi-tech companies will continue on a recovery track from the financial crisis. We are pleased that many CEOs have expressed confidence in the future market and have said they will invest more in the research and development (R&D) of new products and technologies."
This is the fifth anniversary of the Deloitte Technology Fast 50 China Program since this global program was introduced in China in 2005. This program was designed to showcase the countries' emerging innovative companies with great growth potential in the Telecom, Media, and Hi-Tech sectors. Its annual Top lists have become an influential bellwether for global financial and investment circles. For the 2009 Deloitte Technology Fast 50 China Program, the Top 5 companies achieved an electrifying three-year average revenue growth ranging from 1,771.02% to 29,576.86%. The Top 50 China Winning Companies will be entered into the 2009 Deloitte Technology Fast 500 Asia & Pacific Program.
About Shanghai ChemPartner
Founded in 2003, Shanghai ChemPartner Company Ltd. (ChemPartner) is one of the leading contract research organizations, providing medicinal chemistry, discovery biology, pharmacology, DMPK, toxicology, process R&D, analytical development, formulation and contract manufacturing services to over 120 pharmaceutical and biotech companies across the globe. ChemPartner currently has a team of over 1000 scientists including nearly 100 senior scientific leaders with extensive industry experiences gained from leading global pharmaceutical and biotech companies. Headquartered in China, ChemPartner has overseas business development operations at Boston, USA and Copenhagen, Denmark.
ShangPharma is a leading China-based outsourcing partner in pharmaceutical and biotechnology research and development, who provides customized services to international pharmaceutical, biotech, agrochemical and chemical companies. As the holding company of Shanghai ChemPartner Co., Ltd. and Shanghai ChemExplorer Company Ltd., ShangPharma offers global pharmaceutical and biotechnology companies comprehensive services and support for all of their preclinical R&D needs. ShangPharma currently has a team of more than 1,800 professionals, and more than 60% of the employees have post graduate educational experience of Master or Ph.D. degrees. ShangPharma has established comprehensive R&D partnerships with world-class academic institutes, universities as well as healthcare industry and organizations, to contribute more added-value for its clients' success.
Further information is available at http://www.shangpharma.com .
SOURCE Shanghai ChemPartner Company Ltd.
|SOURCE Shanghai ChemPartner Company Ltd.|
Copyright©2009 PR Newswire.
All rights reserved